StemCell Therapy

Puma Biotechnology Inc s chart and data analysis indicates that the stock price has dropped -14.54% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -29.98% . Looking at the past 52 week period, the stock price is down -12.97% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Puma Biotechnology Inc has a positive value of 4.53 compared to overall market.Puma Biotechnology, Inc. is having a Relative Strength Index of 68.39 which indicates the stock is not yet over sold or over bought based on the technical indicators.

For the current week, the company shares have a recommendation consensus of Buy. Puma Biotechnology Inc (NYSE:PBYI) has climbed 10.43% in the past week and advanced 24.81% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 8.78% and the outperformance has advanced to 20.57% for the last 4 weeks period.

Company has reported several Insider transactions to the SEC, on Jan 24, 2017, Steven Lo (Chief Commercial Officer) sold 2,290 shares at 33.24 per share price.On Jan 24, 2017, Charles R Eyler (officer ) sold 820 shares at 33.24 per share price.On Jan 24, 2017, Richard Paul Bryce (SR VP, CLINICAL RESEARCH & DEV) sold 2,293 shares at 33.24 per share price.

Puma Biotechnology Inc (NYSE:PBYI) rose 7.76% or 2.9 points on Friday and made its way into the gainers of the day. After trading began at $37.25 the stock was seen hitting $40.5 as a peak level and $36.7 as the lowest level. The stock ended up at $40.25. The daily volume was measured at 1,377,113 shares. The 52-week high of the share price is $73.27 and the 52-week low is $19.74. The company has a market cap of $1,482 million.

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.

Go here to see the original:
Stock Price of Puma Biotechnology Inc (PBYI) Increases 10.43% - Highland Mirror

This entry was posted on February 21, 2017 at 6:44 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |